Elanco Animal Health Inc ELAN

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived NYSE

Elanco Animal Health Incorporated and its subsidiaries (collectively, Elanco, the Company, we, us, or our) is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets. We partner with farmers, pet owners, veterinarians and society to create value and help our customers improve the health of animals in their care, while also making a meaningful impact on the communities we serve. Our diverse, durable product portfolio is sold in more than 90 countries and serves animals across many species, primarily: dogs and cats (collectively, pet health) and cattle, poultry, swine and sheep (collectively, farm animal). Our purpose – making life better for animals makes life better – inspires us to Go Beyond for animals, our customers, our people and society.

Last close 22.52 2026-10-23
Market cap $11.25B 2026-06-30 share count
52-week range 19.40 - 27.98

Valuation FY2025 figures against the last close

P/S2.4x
P/E—
P/FCF39.6x
EV/EBITDA—
Dividend yield—
Diluted EPS-0.47

Where the revenue comes from as reported in the latest 10-K

Revenue by geography

  • International
  • United States
Revenue by geography, 2 categories over 3 years. The same figures are in the table below. FY2025 International, FY2025: 2.5B (52.6%) 53% International United States, FY2025: 2.2B (47.4%) 47% United States FY2024 International, FY2024: 2.4B (54.1%) 54% United States, FY2024: 2B (45.9%) 46% FY2023 International, FY2023: 2.4B (55.1%) 55% United States, FY2023: 2B (44.9%) 45%
Region FY2025FY2024FY2023
International $2.48B $2.40B $2.43B
United States $2.23B $2.04B $1.98B

As the company reported it, from the “Revenue - Schedule of Disaggregation of Revenue (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $4.71B$4.44B$4.42B$4.41B$4.76B$3.27B$3.07B$3.07B$2.89B$2.91B
Cost of revenue $2.12B$2.00B$1.93B$1.91B$2.13B$1.67B$1.47B$1.57B$1.49B$1.41B
Gross profit $2.59B$2.44B$2.49B$2.50B$2.63B$1.60B$1.60B$1.49B$1.40B$1.50B
R&D $368.0M$344.0M$327.0M$321.0M$369.0M$329.0M$270.0M$246.6M$251.7M$265.8M
SG&A $1.43B$1.31B$1.28B$1.26B$1.40B$997.0M$760.0M$735.2M$779.8M$784.8M
Total operating expenses —$3.95B$5.61B$4.48B$5.33B$3.95B$2.99B$2.95B$3.12B$2.94B
Interest expense ——$277.0M$241.0M$236.0M$150.0M$79.0M$29.6M$0$0
Pre-tax income -$224.0M$488.0M-$1.20B-$72.0M-$571.0M-$677.0M$78.0M$114.1M-$232.6M-$22.4M
Income tax $8.0M$150.0M$36.0M$6.0M$88.0M$103.0M$10.0M$27.6M$78.1M$25.5M
Net income -$232.0M$338.0M-$1.23B-$78.0M-$483.0M-$574.0M$68.0M$86.5M-$310.7M-$47.9M
EPS, basic -0.470.68-2.50-0.16-0.99-1.300.180.28-1.06—
EPS, diluted -0.470.68-2.50-0.16-0.99-1.300.180.28-1.06-0.16
Shares, diluted (wtd. avg.) 496.4M497.3M492.3M488.3M487.2M441.4M370.3M313.7M293.3M293.3M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $545.0M$468.0M$352.0M$345.0M$638.0M$506.0M$345.0M$678.0M$323.4M$258.8M
Receivables $873.0M$805.0M$842.0M$797.0M$833.0M$872.0M$816.9M$651.8M$567.4M—
Inventory $1.74B$1.57B$1.74B$1.54B$1.37B$1.58B$1.05B$1.00B$1.06B—
Total current assets $3.46B$3.21B$3.41B$3.28B$3.27B$3.42B$2.37B$2.50B$2.12B—
Property, plant and equipment —$993.0M$1.03B$999.0M$1.05B$1.32B$955.3M$922.4M$920.3M—
Goodwill $4.78B$4.41B$5.09B$5.99B$6.17B$6.22B$2.99B$2.96B$2.97B—
Other intangibles $3.41B$3.68B$4.49B$4.84B$5.59B$6.39B$2.48B$2.50B$2.67B—
Total assets $13.36B$12.61B$14.36B$15.49B$16.48B$17.69B$8.99B$8.96B$8.94B—
Accounts payable $368.0M$296.0M$270.0M$390.0M$416.0M$501.0M$222.6M$205.2M$203.8M—
Short-term debt —$44.0M$38.0M$388.0M$294.0M$555.0M$24.5M$29.0M$0—
Total current liabilities $1.60B$1.31B$1.24B$1.70B$1.65B$2.08B$818.5M$970.7M$643.1M—
Long-term debt $3.76B$4.32B$5.74B$5.45B$6.03B$5.57B$2.33B$2.44B$0—
Total liabilities $6.81B$6.52B$8.14B$8.20B$8.97B$9.22B$3.44B$3.76B$1.16B—
Retained earnings -$2.18B-$1.95B-$2.29B-$1.06B-$979.0M-$477.0M$84.3M$16.4M$0—
Total equity $6.55B$6.10B$6.22B$7.29B$7.51B$8.46B$5.54B$5.20B$7.78B$7.02B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $560.0M$541.0M$271.0M$452.0M$483.0M-$41.0M$224.0M$487.3M$173.8M$155.9M
Depreciation and amortisation $680.0M$662.0M$694.0M$682.0M$716.0M$517.0M$314.0M$296.0M$318.4M$254.4M
Stock-based compensation $68.0M$55.0M$46.0M$59.0M$66.0M$47.0M$49.0M$26.0M$25.0M$20.4M
Capital expenditure $276.0M$147.0M$140.0M$171.0M$159.0M$135.0M$140.0M$134.5M$98.6M$110.3M
Investing cash flow -$279.0M$1.16B-$169.0M-$179.0M-$530.0M-$4.78B-$235.0M-$127.0M-$964.6M-$182.1M
Financing cash flow -$275.0M-$1.49B-$83.0M-$549.0M$210.0M$4.95B-$305.0M-$35.2M$847.5M-$149.6M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001739104-26-000016.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2B 0 2B 4B 6B Revenue, FY2016: 2.9B Gross profit, FY2016: 1.5B Net income, FY2016: -47.9M Revenue, FY2017: 2.9B Gross profit, FY2017: 1.4B Net income, FY2017: -310.7M Revenue, FY2018: 3.1B Gross profit, FY2018: 1.5B Net income, FY2018: 86.5M Revenue, FY2019: 3.1B Gross profit, FY2019: 1.6B Net income, FY2019: 68M Revenue, FY2020: 3.3B Gross profit, FY2020: 1.6B Net income, FY2020: -574M Revenue, FY2021: 4.8B Gross profit, FY2021: 2.6B Net income, FY2021: -483M Revenue, FY2022: 4.4B Gross profit, FY2022: 2.5B Net income, FY2022: -78M Revenue, FY2023: 4.4B Gross profit, FY2023: 2.5B Net income, FY2023: -1.2B Revenue, FY2024: 4.4B Gross profit, FY2024: 2.4B Net income, FY2024: 338M Revenue, FY2025: 4.7B Gross profit, FY2025: 2.6B Net income, FY2025: -232M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $2.91B $2.89B $3.07B $3.07B $3.27B $4.76B $4.41B $4.42B $4.44B $4.71B
Gross profit $1.50B $1.40B $1.49B $1.60B $1.60B $2.63B $2.50B $2.49B $2.44B $2.59B
Net income -$47.9M -$310.7M $86.5M $68.0M -$574.0M -$483.0M -$78.0M -$1.23B $338.0M -$232.0M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Restructuring or exit costs A restructuring: layoffs, a plant closure, a business being wound down. Item 2.05
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%